| Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461) (NCT03368053) | GlaxoSmithKline | 2017-12-14 |
| GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers (NCT03231943) | ViiV Healthcare | 2017-09-19 |
| Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men (NCT03310515) | ViiV Healthcare | 2017-08-31 |
| A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir (NCT03234036) | GlaxoSmithKline | 2017-08-02 |
| Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects (NCT03149848) | ViiV Healthcare | 2017-06-06 |
| Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine (NCT03078556) | ViiV Healthcare | 2017-03-27 |
| Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults (NCT03045861) | GlaxoSmithKline | 2017-03-17 |
| Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers (NCT02478463) | ViiV Healthcare | 2017-02-27 |
| Phase 4 Study of Dolutegravir (DTG) in Russian Federation (NCT03314064) | ViiV Healthcare | 2016-12-08 |
| Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (NCT02951052) | ViiV Healthcare | 2016-10-28 |
| Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet (NCT02893488) | ViiV Healthcare | 2016-09-01 |
| A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects (NCT02859259) | ViiV Healthcare | 2016-08-12 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) (NCT02831673) | ViiV Healthcare | 2016-07-21 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) (NCT02831764) | ViiV Healthcare | 2016-07-18 |
| Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC (NCT03275701) | Mills Clinical Research | 2016-07-01 |
| A Study to Evaluate the Effect of High Fat Meal on Cabotegravir (NCT02799264) | ViiV Healthcare | 2016-06-01 |
| Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (NCT02741557) | ViiV Healthcare | 2016-05-11 |
| A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176 (NCT02715479) | ViiV Healthcare | 2016-04-01 |
| Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing (NCT02805556) | ViiV Healthcare | 2016-03-15 |
| Single and Repeated Dose Escalation Study of GSK2838232 (NCT02795754) | GlaxoSmithKline | 2016-03-01 |
| A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects (NCT02666053) | ViiV Healthcare | 2016-01-27 |
| A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone (NCT02666001) | ViiV Healthcare | 2016-01-12 |
| A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers (NCT02634073) | ViiV Healthcare | 2016-01-01 |
| A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects (NCT02576119) | ViiV Healthcare | 2015-10-19 |
| Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects (NCT02539576) | ViiV Healthcare | 2015-10-01 |
| Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet (NCT02508064) | ViiV Healthcare | 2015-08-03 |
| Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment (NCT02354937) | ViiV Healthcare | 2015-07-13 |
| A Open-label, Drug-Drug Interaction With Maraviroc (DDI) (NCT02480894) | ViiV Healthcare | 2015-07-07 |
| A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI) (NCT02480881) | ViiV Healthcare | 2015-07-07 |
| Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults (NCT02415595) | ViiV Healthcare | 2015-05-12 |
| Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (NCT02345707) | ViiV Healthcare | 2015-03-01 |
| Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects (NCT02373930) | ViiV Healthcare | 2015-02-01 |
| Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection (NCT02178592) | ViiV Healthcare | 2015-01-23 |
| ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (NCT02075593) | ViiV Healthcare | 2014-12-17 |
| A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (NCT02289495) | GlaxoSmithKline | 2014-11-18 |
| A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (NCT02289482) | GlaxoSmithKline | 2014-11-17 |
| A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) (NCT02277600) | ViiV Healthcare | 2014-11-05 |
| Food Effect Study With BMS-955176 (NCT02273947) | ViiV Healthcare | 2014-10-23 |
| Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (NCT02185300) | ViiV Healthcare | 2014-07-01 |
| Study of Combined Oral Contraceptive Effects in Female Subjects (NCT02157467) | ViiV Healthcare | 2014-06-02 |
| Drug-drug Interaction (DDI) Rifabutin (NCT02138084) | ViiV Healthcare | 2014-05-14 |
| A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (NCT02120352) | ViiV Healthcare | 2014-04-28 |
| A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (NCT02105987) | ViiV Healthcare | 2014-04-01 |
| Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR) (NCT02076178) | ViiV Healthcare | 2014-03-27 |
| Relative Bioavailability Study With BMS-955176 (NCT02095886) | ViiV Healthcare | 2014-03-25 |
| A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (NCT02076386) | ViiV Healthcare | 2014-03-04 |
| Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (NCT02082808) | ViiV Healthcare | 2014-03-01 |
| Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects (NCT02064374) | ViiV Healthcare | 2014-02-01 |
| A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects (NCT02059031) | ViiV Healthcare | 2014-02-01 |
| DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV) (NCT02063360) | ViiV Healthcare | 2014-02-01 |
| Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction (NCT02027454) | ViiV Healthcare | 2014-01-01 |
| A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (NCT01910402) | ViiV Healthcare | 2013-08-22 |
| Study to Evaluate a HIV Drug for the Treatment of HIV Infection (NCT01803074) | ViiV Healthcare | 2013-04-04 |
| Single Dose Escalation Study of GSK2838232 in Healthy Subjects (NCT01802918) | GlaxoSmithKline | 2013-02-18 |
| A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects (NCT01754116) | ViiV Healthcare | 2013-01-01 |
| Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine (NCT01641809) | ViiV Healthcare | 2012-08-06 |
| Evaluation of the Bioequivalence of a Combined Formulated Tablet (NCT01622790) | ViiV Healthcare | 2012-06-01 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects (NCT01593046) | ViiV Healthcare | 2012-05-01 |
| A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697). (NCT01563328) | ViiV Healthcare | 2012-03-01 |
| A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects (NCT01499199) | ViiV Healthcare | 2012-01-01 |
| Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol (NCT01498861) | ViiV Healthcare | 2011-12-01 |
| Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (NCT01449929) | ViiV Healthcare | 2011-10-31 |
| Drug Interaction Study Between Dolutegravir and Prednisone (NCT01425099) | ViiV Healthcare | 2011-09-01 |
| Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets (NCT01366547) | ViiV Healthcare | 2011-06-01 |
| A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (NCT01328041) | ViiV Healthcare | 2011-05-01 |
| Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers (NCT01231542) | ViiV Healthcare | 2011-05-01 |
| A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects (NCT01332565) | ViiV Healthcare | 2011-04-01 |
| A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects (NCT01273103) | ViiV Healthcare | 2011-01-01 |
| GSK1349572 Hepatic Impairment Study (NCT01231529) | ViiV Healthcare | 2010-11-19 |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (NCT01231555) | ViiV Healthcare | 2010-11-18 |
| A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (NCT01231516) | ViiV Healthcare | 2010-10-26 |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (NCT01199731) | ViiV Healthcare | 2010-10-05 |
| A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects. (NCT01195974) | ViiV Healthcare | 2010-09-14 |
| A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435 (NCT01209117) | ViiV Healthcare | 2010-09-01 |
| A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects. (NCT01138072) | GlaxoSmithKline | 2010-06-01 |
| A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) (NCT01102972) | ViiV Healthcare | 2010-04-01 |
| GSK1349572 Relative Bioavailability Study (NCT01098513) | ViiV Healthcare | 2010-04-01 |
| Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (NCT01068925) | ViiV Healthcare | 2010-02-15 |
| A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761 (NCT01031472) | ViiV Healthcare | 2009-12-21 |
| Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults. (NCT00945282) | ViiV Healthcare | 2009-10-20 |
| A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (NCT00951015) | ViiV Healthcare | 2009-07-30 |
| DDI Study of Etravirine and GSK1265744 (NCT00920296) | GlaxoSmithKline | 2009-07-01 |
| Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929) (NCT00920426) | ViiV Healthcare | 2009-06-09 |
| HIV Treatment and CVD Events (NCT01054638) | ViiV Healthcare | 2009-03-01 |
| Fosamprenavir in Pts With Hepatic Impairment (NCT01054586) | GlaxoSmithKline | 2009-01-01 |
| GSK1349572 Drug Interaction Study With Protease Inhibitors (NCT00774735) | GlaxoSmithKline | 2008-10-01 |
| GSK706769/KALETRA Drug-drug Interaction Study (NCT00723775) | GlaxoSmithKline | 2008-07-24 |
| Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults (NCT00708110) | ViiV Healthcare | 2008-06-01 |
| Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal. (NCT00812318) | ViiV Healthcare | 2008-06-01 |
| GSK706769 Repeat Dose Study (NCT00711386) | GlaxoSmithKline | 2008-05-16 |
| Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 (NCT00453440) | ViiV Healthcare | 2007-03-20 |
| Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients (NCT00441688) | ViiV Healthcare | 2007-03-15 |
| Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status (NCT01077557) | ViiV Healthcare | 2006-11-01 |
| A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects. (NCT00386347) | GlaxoSmithKline | 2006-10-01 |
| A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects (NCT00363142) | GlaxoSmithKline | 2006-05-01 |
| KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks (NCT00085943) | GlaxoSmithKline | 2004-05-01 |
| Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (NCT00071760) | ViiV Healthcare | 2003-10-23 |
| Fosamprenavir Expanded Access (NCT00240552) | ViiV Healthcare | 2003-07-01 |
| A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects (NCT00296504) | ViiV Healthcare | 2001-11-01 |
| GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV (NCT03462810) | ViiV Healthcare | |